Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at financialmarketpress.com, will continue to monitor these healthtech companies to see if the momentum continues. FinancialMarketPress.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent NTLA Stock Price: $62.53
Summary: Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.'
David Lebovitz analyst at Citigroup reiterates coverage on Intellia Therapeutics (NTLA) stock in the energy sector with a Sell rating and has set NTLA's stock price target at $ 50.
TipRanks.com reports that Intellia Therapeutics currently has 15 analysts offering 12-month price targets on NTLA and the consensus is a Moderate Buy rating with an average stock price target of $110.46. The most recent NTLA stock price we have is $62.53 and we are not making any NTLA forecasts at this time.
In addition, TradingView issued a n/a rating for NTLA over the next month, Barchart.com has a hold rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on NTLA. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on NTLA, please click here >>
Beauty Health, SKIN
Recent SKIN Stock Price: $11.8
Summary: The Beauty Health Company is a beauty health company. Its flagship brand HydraFacial is a non-invasive and approachable beauty health platform and ecosystem with a powerful community of estheticians, consumers and partners, bridging medical and consumer retail to democratize and personalize skin care solutions for the masses. The Beauty Health Company, formerly known as Vesper Healthcare Acquisition Corp., is based in CHICAGO, Utah.
Oliver Chen analyst at Cowen & Co. reiterates coverage on Beauty Health (SKIN) stock in the energy sector with a Buy rating and has set SKIN's stock price target at $ 20.
TipRanks.com reports that Beauty Health currently has 8 analysts offering 12-month price targets on SKIN and the consensus is a Strong Buy rating with an average stock price target of $22.63. The most recent SKIN stock price we have is $11.8 and we are not making any SKIN forecasts at this time.
In addition, TradingView issued a n/a rating for SKIN over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on SKIN. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SKIN, please click here >>
Edwards Lifesciences, EW
Recent EW Stock Price: $87.19
Summary: Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
Suraj Kalia analyst at Oppenheimer reiterates coverage on Edwards Lifesciences (EW) stock in the energy sector with a Buy rating and has set EW's stock price target at $ 128.
TipRanks.com reports that Edwards Lifesciences currently has 16 analysts offering 12-month price targets on EW and the consensus is a Strong Buy rating with an average stock price target of $116.13. The most recent EW stock price we have is $87.19 and we are not making any EW forecasts at this time.
In addition, TradingView issued a n/a rating for EW over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on EW. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on EW, please click here >>
Alcon, ALC
Recent ALC Stock Price: $65.23
Summary: Alcon Inc. researches, develops, manufactures, distributes, and sells a full suite of eye care products. Alcon operates within two segments, Surgical and Vision Care. The Surgical segment is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery, and includes implantables, consumables, and surgical equipment required for these procedures. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, and a comprehensive portfolio of ocular health products, including products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers.
Ryan Zimmerman analyst at BTIG reiterates coverage on Alcon (ALC) stock in the energy sector with a Buy rating and has set ALC's stock price target at $ 80.
TipRanks.com reports that Alcon currently has 12 analysts offering 12-month price targets on ALC and the consensus is a Moderate Buy rating with an average stock price target of $79.71. The most recent ALC stock price we have is $65.23 and we are not making any ALC forecasts at this time.
In addition, TradingView issued a n/a rating for ALC over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ALC. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ALC, please click here >>
The editors at financialmarketpress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinancialMarketPress.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinancialMarketPress.com.
==============================================================================
